CA2351400A1 - Derives d'uree arylpiperidine et aryl-1,2,5,6-tetrahydropyridine presentant une activite de recepteur de 5ht1a - Google Patents

Derives d'uree arylpiperidine et aryl-1,2,5,6-tetrahydropyridine presentant une activite de recepteur de 5ht1a Download PDF

Info

Publication number
CA2351400A1
CA2351400A1 CA002351400A CA2351400A CA2351400A1 CA 2351400 A1 CA2351400 A1 CA 2351400A1 CA 002351400 A CA002351400 A CA 002351400A CA 2351400 A CA2351400 A CA 2351400A CA 2351400 A1 CA2351400 A1 CA 2351400A1
Authority
CA
Canada
Prior art keywords
compound
disorder
hydrogen
phenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002351400A
Other languages
English (en)
Inventor
Gan Zhang
Michael Gerard Kelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2351400A1 publication Critical patent/CA2351400A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés représentés par la formule (A), utiles pour traiter les troubles du système nerveux, notamment l'anxiété, la dépression, la panique, la narcomanie, l'alcoolisme, les dysfonctionnements sexuels, les troubles du sommeil, la migraine, l'obésité, les troubles cognitifs et les maladies neurodégénératives.
CA002351400A 1998-12-17 1999-12-16 Derives d'uree arylpiperidine et aryl-1,2,5,6-tetrahydropyridine presentant une activite de recepteur de 5ht1a Abandoned CA2351400A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21334098A 1998-12-17 1998-12-17
US09/213,340 1998-12-17
PCT/US1999/029907 WO2000035875A1 (fr) 1998-12-17 1999-12-16 Derives d'uree arylpiperidine et aryl-1,2,5,6-tetrahydropyridine presentant une activite de recepteur de 5ht1a

Publications (1)

Publication Number Publication Date
CA2351400A1 true CA2351400A1 (fr) 2000-06-22

Family

ID=22794731

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002351400A Abandoned CA2351400A1 (fr) 1998-12-17 1999-12-16 Derives d'uree arylpiperidine et aryl-1,2,5,6-tetrahydropyridine presentant une activite de recepteur de 5ht1a

Country Status (7)

Country Link
EP (1) EP1140831A1 (fr)
JP (1) JP2002532472A (fr)
CN (1) CN1335835A (fr)
AU (1) AU3123500A (fr)
BR (1) BR9916220A (fr)
CA (1) CA2351400A1 (fr)
WO (1) WO2000035875A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004215344B2 (en) * 2003-02-24 2010-06-24 Arena Pharmaceuticals, Inc. Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106074B2 (en) 2001-07-13 2012-01-31 Pierre Fabre Medicament Pyridin-2-yl-methylamine derivatives for treating opiate dependence
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AU2003300726A1 (en) * 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research N-aryloxypropanolyl-n'-phenethyl-urea
US6962945B2 (en) 2004-03-26 2005-11-08 Council Of Scientific And Industrial Research N-aryloxypropanolyl-N′-phenethyl-urea
KR101871011B1 (ko) 2010-09-22 2018-06-25 아레나 파마슈티칼스, 인크. Ｇｐｒ１１９ 수용체의 조절제 및 그와 관련된 장애의 치료
UA126268C2 (uk) 2015-01-06 2022-09-14 Арена Фармасьютікалз, Інк. СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub>
EA201890096A1 (ru) 2015-06-22 2018-08-31 Арена Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКАЯ L-АРГИНИНОВАЯ СОЛЬ (R)-2-(7-(4-ЦИКЛОПЕНТИЛ-3-(ТРИФТОРМЕТИЛ)БЕНЗИЛОКСИ)-1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ (СОЕДИНЕНИЯ 1) ДЛЯ ПРИМЕНЕНИЯ ПРИ РАССТРОЙСТВАХ, СВЯЗАННЫХ С S1P-РЕЦЕПТОРОМ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882432A (en) * 1989-01-09 1989-11-21 American Home Products Corporation Polycyclic-carbamic acid piperazinoalkyl esters and amides
FR2664592B1 (fr) * 1990-07-10 1994-09-02 Adir Nouveaux derives de la piperidine, de la tetrahydropyridine et de la pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9314758D0 (en) * 1993-07-16 1993-08-25 Wyeth John & Brother Ltd Heterocyclic derivatives
DE19615232A1 (de) * 1996-04-18 1997-10-23 Merck Patent Gmbh Neue Carbamoylderivate und deren Verwendung als 5-HT ¶1¶¶A¶-Antagonisten

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004215344B2 (en) * 2003-02-24 2010-06-24 Arena Pharmaceuticals, Inc. Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism

Also Published As

Publication number Publication date
WO2000035875A1 (fr) 2000-06-22
JP2002532472A (ja) 2002-10-02
CN1335835A (zh) 2002-02-13
AU3123500A (en) 2000-07-03
EP1140831A1 (fr) 2001-10-10
BR9916220A (pt) 2001-09-11

Similar Documents

Publication Publication Date Title
US6239126B1 (en) Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives
US7790753B2 (en) Derivatives of N-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
EP0623120A1 (fr) Derives d&#39;acide piperidineacetique servant d&#39;inhibiteurs de l&#39;agregation plaquettaire sanguine dependante du fibrinogene
US6028082A (en) Human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them
CA2172377A1 (fr) Nouveaux lactames du type 4-piperidinyle substitues utilises en tant qu&#39;antagonistes du recepteur de neurokinine 2 dans le traitement de l&#39;asthme
US5198449A (en) N-substituted alpha-arylazacycloalkylmethanamines and their use as cardiovascular agents
US6503928B2 (en) Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives
CA2351400A1 (fr) Derives d&#39;uree arylpiperidine et aryl-1,2,5,6-tetrahydropyridine presentant une activite de recepteur de 5ht1a
US4292321A (en) 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof
EP1140830B1 (fr) Derives d&#39;arylpiperidine et d&#39;aryl-1,2,5,6-tetrahydropyridine amide agissant comme recepteur de 5ht1a
US6242448B1 (en) Trisubstituted-oxazole derivatives as serotonin ligands
US6518272B2 (en) Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US6255302B1 (en) 1,4-piperazine derivatives
US6066637A (en) Indolyl derivatives as serotonergic agents
US4411904A (en) Diphenylpropanamines, compositions thereof and use thereof
AU3123100A (en) 1,4-piperazine derivatives having 5ht1a receptor activity
CA2330437A1 (fr) Derives d&#39;indolyle en tant qu&#39;agents serotoninergiques
MXPA01006064A (en) Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine urea derivatives having 5ht1a receptor activity
US4364954A (en) Diphenylpropanamines, compositions thereof and use thereof
CA2346729A1 (fr) Derives d&#39;ureidopiperidine comme antagonistes selectifs des recepteurs nk3 humains
EP1076658A1 (fr) Agents serotoninergiques
US6344458B1 (en) Piperazine ethylamide derivatives
AU3124100A (en) Piperazine ethylamide derivatives with 5-ht1a receptor activity
MXPA01006065A (en) 1,4-piperazine derivatives having 5ht1a receptor activity
MXPA98008594A (en) Piperidines and pyrolrolidi

Legal Events

Date Code Title Description
FZDE Dead